Persistence of pharmacological migraine prevention based on statutory health insurance claims data from Germany: a retrospective cohort study.

Migraine is a significant health issue affecting many people in Germany. About 15% of women and 6% of men suffer from migraines. These headaches cause a large loss of healthy life years. Preventive treatments aim to lessen how often migraines occur and how severe they are. This study looked at how well patients stick with their migraine medications. Researchers used health insurance data to track prescription patterns. They focused on traditional oral drugs and a specific injection treatment called BoNTA. The study examined patients who later started using a new class of medications called aCGRP monoclonal antibodies. It analyzed patients who had a migraine diagnosis and received their first aCGRP prescription in late 2021. The findings provide insights into the real-world use of migraine prevention treatments and how long patients continue using them. Clinical relevance: This study highlights the need for effective migraine prevention strategies to improve patient adherence and overall treatment outcomes.